Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(3.09)
# 1,216
Out of 4,876 analysts
103
Total ratings
46.67%
Success rate
1.02%
Average return
Main Sectors:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRNA Verona Pharma | Maintains: Overweight | $90 → $100 | $93.59 | +6.85% | 1 | Jun 11, 2025 | |
| UTHR United Therapeutics | Initiates: Overweight | $405 | $283.68 | +42.77% | 1 | Jun 2, 2025 | |
| VNDA Vanda Pharmaceuticals | Assumes: Overweight | $13 | $4.86 | +167.77% | 1 | May 14, 2025 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $90 | $54.79 | +64.26% | 15 | Feb 20, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $444.52 | +7.98% | 22 | Feb 11, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $55 | $46.21 | +19.02% | 9 | Feb 4, 2025 | |
| GILD Gilead Sciences | Reiterates: Neutral | $80 | $110.23 | -27.42% | 10 | Dec 11, 2024 | |
| OMER Omeros | Reiterates: Neutral | n/a | $3.30 | - | 1 | Nov 14, 2024 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Neutral | $1,015 | $518.00 | +95.95% | 8 | Oct 23, 2024 | |
| AMGN Amgen | Reiterates: Overweight | $405 | $276.83 | +46.30% | 2 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $220 | $320.69 | -31.40% | 23 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $10 | $8.66 | +15.47% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6.5 | $3.74 | +73.80% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $46.75 | +54.01% | 1 | Apr 13, 2023 |
Verona Pharma
Jun 11, 2025
Maintains: Overweight
Price Target: $90 → $100
Current: $93.59
Upside: +6.85%
United Therapeutics
Jun 2, 2025
Initiates: Overweight
Price Target: $405
Current: $283.68
Upside: +42.77%
Vanda Pharmaceuticals
May 14, 2025
Assumes: Overweight
Price Target: $13
Current: $4.86
Upside: +167.77%
BioMarin Pharmaceutical
Feb 20, 2025
Reiterates: Overweight
Price Target: $90
Current: $54.79
Upside: +64.26%
Vertex Pharmaceuticals
Feb 11, 2025
Reiterates: Overweight
Price Target: $480
Current: $444.52
Upside: +7.98%
Bristol-Myers Squibb Company
Feb 4, 2025
Maintains: Neutral
Price Target: $50 → $55
Current: $46.21
Upside: +19.02%
Gilead Sciences
Dec 11, 2024
Reiterates: Neutral
Price Target: $80
Current: $110.23
Upside: -27.42%
Omeros
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $3.30
Upside: -
Regeneron Pharmaceuticals
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $518.00
Upside: +95.95%
Amgen
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $276.83
Upside: +46.30%
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $320.69
Upside: -31.40%
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $8.66
Upside: +15.47%
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $3.74
Upside: +73.80%
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $46.75
Upside: +54.01%